Search Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapySolid TumorsProtocol groupHead and Neck OncologyradiotherapyDiseaseHead and Neck Tumors (Squamous Cell)Nasopharyngeal CarcinomaSubgroupHPV positivePD-L1 with CPS from 1ICD10C11.-C11.8C11.9C76.0MeSHHypopharyngeal NeoplasmsLaryngeal NeoplasmsMouth NeoplasmsNasopharyngeal CarcinomaOropharyngeal NeoplasmsSquamous Cell Carcinoma of Head and NeckSequenceCETU(400/250)/CISP100, Head and Neck Tumors, C1 (PID1246) -|- CETU250/CISP100, C2+ (PID1271)CETU(400/250)/DOCE75/CISP100/FU700, Head and Neck Tumors, C1 (PID1348) -|- CETU250/CISP100/DOCE75/FU700, C2-3 (PID1349)CETU(400/250)/PACL175/CISP75, Head and Neck Tumors, C1 (PID1273) -|- CETU250/PACL175/CISP75, C2+ (PID1274)CETU400, Head and Neck Tumors, C1 (PID1220) -|- CETU250, C2+ (PID1221)CETU400/CRBP5/FU1000, Head and Neck Tumors, C1 (PID623) -|- CETU250/CRBP5/FU1000, C2+ (PID337)CETU400/PACL40/CRBP2/Radiation, Head and Neck Tumors, C1 (PID622) -|- CETU250/PACL40/CRBP2/Radiation, Head and Neck Tumors, C2+ (PID621)CETU400/PACL80, Head and Neck Tumors, C1 (PID707) -|- CETU250/PACL80, C2+ (PID708)CETU400/PACL90/CRBP2, Head and Neck Tumors, C1 (PID1242) -|- C2-6 (PID1243) -|- C7-11 (PID1244)CETU400/Radiation, Head and Neck Tumors, C1 (PID1194) -|- CETU250/Radiation, C2+ (PID1195)CISP12/FU600/Radiation, Head and Neck Tumors, C1-2 (PID2059) -|- C3 (PID2060) -|- C4 (PID2062)CISP100/Radiatio, Head and Neck Tumors (PID1334) -|- CISP100/CAPE1000, Nasopharyngeal Ca (PID1784).DOCE60/CISP60/FU600, Nasopharyngeal Ca (PID1373) -|- CISP100/Radiation, Head and Neck Tumors (PID1334)DOCE75/CISP75/FU750, Head and Neck Tumors (PID1102) -|- CRBP1.5/Radiation (PID1282)GEMC1000/CISP80, Nasopharyngeal Ca (PID1325) -|- CISP100/Radiation (PID1334)GORTEC: TPEx (CETU(400/250)/DOCE75/CISP75), Head and Neck Tumors, C1 (PID1275) -|- TPEx (CETU250/DOCE75/CISP75), C2+ (PID1276)KEYNOTE-048: PEMB200/CISP100/FU1000, Head and Neck Tumors, First Line (PID1447) -|- PEMB200 (PID1445)KEYNOTE-048: PEMB200/CRBP5/FU1000, Head and Neck Tumors, first-line (PID1446) -|- PEMB200 (PID1445)ChemotherapyChemo-substanceCarboplatinCetuximabCisplatinDocetaxelFluorouracilMethotrexateMitomycinNivolumabPaclitaxelPembrolizumabChemo-substanceCarboplatinCetuximabCisplatinDocetaxelFluorouracilMethotrexateMitomycinNivolumabPaclitaxelPembrolizumabChemo-substanceCarboplatinCetuximabCisplatinDocetaxelFluorouracilMethotrexateMitomycinNivolumabPaclitaxelPembrolizumabChemo-substanceCarboplatinCetuximabCisplatinDocetaxelFluorouracilMethotrexateMitomycinNivolumabPaclitaxelPembrolizumabNo. Substances1234 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronHydrocortisoneMagnesiumMagnesium sulfateMinocyclinePalonosetronPegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronHydrocortisoneMagnesiumMagnesium sulfateMinocyclinePalonosetronPegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronHydrocortisoneMagnesiumMagnesium sulfateMinocyclinePalonosetronPegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronHydrocortisoneMagnesiumMagnesium sulfateMinocyclinePalonosetronPegfilgrastimPotassium chlorideNo. Substances12345678101112Protocol classificationTherapy classificationalternativecurrent standardIntensityLow doseStandard doseTherapy indicationFirst lineRelapse therapySecond lineseveral possibleTherapy phaseInductionneoadjuvantPre-phaseTherapy intentioncurativepalliativeRisksAllergic ReactionAnemia Hb below 8g/dlAnemia Hb below 10g/dlAstheniaCardiotoxicityConstipationDehydrationDiarrheaDysphagiaDyspneaEmetogenicity (MASCC/ESMO)EsophagitisExanthema, AcneiformFatigueFebrile NeutropeniaGastrointestinal ToxicityHeadacheHepatotoxicityHypertensionHyperthyroidismHypocalcemiaHypokalemiaHypomagnesemiaHyponatremiaHypothyroidismIncrease AminotransferasesInfectionsInfusion ReactionLeukopeniaLymphopeniaMucositisNail ChangesNephrotoxicityNeuropathyNeurotoxicityNeutropeniaOral MucositisOtotoxicityPainPneumoniaPneumonitisPruritusPyrexiaRadiation DermatitisRashRenal FailureSepsisThrombocytopenia below 50 000/µlThromboembolic Event only studiesPublicationAuthorAdelstein DBauml JBauml J / Cohen EBonner J Bonner JBossi PBrizel DMBudach V Burtness BCalais GCooper JFerris RFury MGhi MGrau JGuardiola EGuigay JHaddad RHitt RMaring SMedina JAMehanna HNoronha VPatil VMPosch DPosner MSamlowski ESuntharalingam MTao Y Vermorken JVermorken JBWanebo HDiseasefortgeschrittener Kopf-Hals-Tumor, Erstlinie, Stadium III-IV, ECOG 0-1fortgeschrittenes Oropharynxkarzinom, nicht metastasiert, Stadium III-IV, Karnofsky <60Karzinom des Oro- und, Hypopharynx, Larynx, Stadium III und IV, nicht metastasiert, Erstlinie, Karnofsky > 60Kopf-Hals-Tumor,nicht-metastasiert, cisplatinungeeignet, ECOG 0-1Kopf-Hals-Tumoren (Plattenepithel-), adjuvant, ECOG 0-1Kopf-Hals-Tumoren (Plattenepithel-), resektabel, Stadium III-IV, ECOG 0-1Kopf-Hals-Tumoren, cTx cNx cM0, nicht cisplatingeeignet, ECOG 0-2Kopf-Hals-Tumoren, nicht resektabel, UICC Stadium III/IV, ECOG 0-1Kopf-Hals-Tumoren, Plattenepithel-, Erstlinie, ECOG 0-1Kopf-Hals-Tumoren, Plattenepithel-Ca, cT3/cT4, cN0-3, cM0 (bei Zungengrund-Ca max. cT2cN0), 18-75J., ECOG 0-2Kopf-Hals-Tumoren, Stadium III -IV, nicht metastasiert, Erstlinie, ECOG 0-1Kopf-Hals-Tumoren, Stadium III oder IV, ohne Fernmetastasen, Erstlinientherapie, ECOG 0-2Kopf-Hals-Tumoren, Stadium IV, platinresistent, Rezidivtherapie, ECOG: 0-2local rezidivierte oder metastasierte Kopf-Hals-Tumoren, Erstlinie, ECOG 0-2Lokal fortgeschrittene Kopf-Hals-Tumoren, Stadium III und IV, adjuvant oder definitive Chemo-Radiotherapie ECOG 0-2lokal fortgeschrittenes, nicht reserzierbares Plattenepithel-Karzinom des Kopf/Halses, Stadium III-IV,M0 Erstlinie, Karnofsky >70Lokal fortgeschrittenes, nicht resezierbares Plattenepithelzellkarzinom des Kopf-Hals-Bereichsmetastasierter oder rezidivierter Kopf-Hals-Tumor, Stadium III-IV, nach Cisplatin, Karnofsky > 60Neudiagnostizierter, lokal fortgeschrittener Kopf-Hals-Tumor, Stadium III-IV, Plattenepithel-, ECOG 0-1neudiagnostizierter, lokal fortgeschrittener Kopf-Hals-Tumor, Stadium III-IV, Plattenepithel-, ECOG 0-1Nicht resezierbare Kopf-Hals-Tumoren (Plattenepithel-), Stadium III - IV, ECOG 0-1Oropharynxkarzinom (Plattenepithel), HPV-positiv und low-risk (nie Raucher oder weniger als 10 PY), T3N0–T4N0, and T1N1–T4N3, ECOG 0-1rezidivierende oder metastasierte Kopf-Hals-Tumoren, Zweitlinie, ECOG 0-2Rezidivierte oder metastasierte Kopf-Hals-Tumoren (Plattenepithel-), ECOG 0-1Rezidivierte oder metastasierte Kopf-Hals-Tumoren (Plattenepithel-), Erstlinie, ECOG 0-1rezidivierte oder metastasierte Kopf-Hals-Tumoren (Plattenepithel-), Erstlinie, ECOG 0-1Rezidivierte oder metastasierte Kopf-Hals-Tumoren (Plattenepithel-), Erstlinie, ECOG 0-1Rrezidivierte oder metastasierte Kopf-Hals-Tumoren, Erstlinie, ECOG 0-2rezidivierter oder metastasierter Kopf-Hals-Tumor, Erstlinie, ECOG 0-1rezidiviertes/metastasiertes, platin- und cetuximabrefraktäres Plattenepithelzellkarzinom des Kopf-Hals-Bereichs, ECOG 0-2 rezidiviertes oder metastasiertes Plattenepithelkarzinom des Larynx oder Pharynx, Karnofsky > 70wiederkehrender oder metastasierter Kopf-Hals-Tumor nach PlatintherapieWiederkehrendes oder metastasiertes Plattenepithel-Karzinom des Kopf und Halses, Karnofsky >70, ErstlinieWiederkehrendes oder metastasiertes Plattenepithelkarzinom des Larynx oder Pharynx, Karnofsky > 70OriginAntwerp University Hospital, Department of Medical Oncology, Edegem, BelgiumCentre Hospitalier Universitaire Tours, France, 94-01 French Head and Neck Oncology and Radiotherapy GroupCHU Jean Minjoz, Service Oncologie medicale, Cedex, FranceCleveland Clinic Foundation, ClevelandDana–Farber Cancer Institute, Boston, TAX 324 Study GroupDepartment of Internal Medicine, Yale University School of Medicine, Eastern Cooperative Oncology Group Study Department of Medical Oncology, Centre Antoine Lacassagne, Nice, TPEx, GORTEC studyDepartment of Medical Oncology, Dana Farber Cancer Institute, BostonDepartment of Medical Oncology, Tata Memorial Hospital, Parel, Mumbai, IndiaDepartment of Medical Oncology, University Hospital Antwerp, Edegem, BelgiumDepartment of Medicine, Memorial Sloan-Kettering Cancer Center, New YorkDepartment of Medicine, University of Alabama, BirminghamDepartment of Radiation Oncology, University Hospital of Muenster, Muenster, GermanyDepartment of Radiation Oncology, University of Maryland School of Medicine, Baltimore BDDepartment of Surgery, Landmark Medical Center, Woonsocket, ECOG-ACRIN trial (E2303)Deptartment of Internal Medicine I und CCC, Medical University of ViennaDuke Comprehensive Cancer Center, Duke University Medical Center, Durham, USAGORTEC 2015-01 PembroRadHead and Neck Medical Oncology, Fondazione IRCCS, Istituto Nazionale dei Tumori, MilanHead and Neck Oncology, Dana Farber Cancer Institute, arvard Medical School, Boston, MassachusettsInstitute for Head and Neck Studies and Education (InHANSE), University of Birmingham, UK, De-ESCALaTE HPV trialMedical Oncology Department, Ospedale dell’Angelo, Venezia, the GSTTC Italian Study GroupNew York University Medical Center, New York, Radiation Therapy Oncology Group 9501/IntergroupOhio State University Comprehensive Cancer Center, Ohio State University, ColumbusOncology Department, Institut Clinic de Malalties Hemato-Oncologiques, University of BarcelonaServicio de Oncologia Radioterapica, Hospital Clinico Universitario, Malaga, SpainSpanish Head and Neck Cancer Cooperative Group, TTCCTata Memorial Hospital, Homi Bhabha National Institute (HBNI), Mumbai, IndiaUniversitair Ziekenhuis Antwerpen, Edegem, BelgiumUniversity Hospitals Charite, Berlin, German Cancer Society 95-06 trialUniversity of Pennsylvenia, PhiladelphiaUniversity of Pennsylvenia, Philadelphia, Keynote-40University of Utah Health Science Center, Salt Lake City, Utah, A Southwest Oncology GroupYale School of Medicine and Yale Cancer Center, New Haven, CT, USA, Keynote-48Protocols in Revision 50 protocols foundProtocols under revision.Carboplatin 1.5 / Radiation, Head and Neck Tumors (PID1282)Carboplatin 70 / Fluorouracil 600 / Radiation, Oropharyngeal Carcinoma (PID1708)Cetuximab (400/250) / Cisplatin 100, Head and Neck Tumors, Cycle 1 (PID1246)Cetuximab (400/250) / Docetaxel 75 / Cisplatin 100 / Fluorouracil 700, Head and Neck Tumors, Cycle 1 (PID1348)Cetuximab (400/250) / Docetaxel 75 / Cisplatin 75, Head and Neck Tumors, Cycle 1 (PID1275)Cetuximab (400/250) / Paclitaxel 175 / Cisplatin 75, Head and Neck Tumors, Cycle 1 (PID1273)Cetuximab 250 / Carboplatin 5 / Fluorouracil 1000, Head and Neck Tumors, C2+ (PID337)Cetuximab 250 / Cisplatin 100 / Docetaxel 75 / Fluorouracil 700, Head and Neck Tumors, Cycle 2-3 (PID1349)Cetuximab 250 / Cisplatin 100, Head and Neck Tumors, Cycle 2+ (PID1271)Cetuximab 250 / Docetaxel 75 / Cisplatin 75, Head and Neck Tumors, Cycle 2+ (PID1276)Cetuximab 250 / Paclitaxel 175 / Cisplatin 75, Head and Neck Tumors, Cycle 2+ (PID1274)Cetuximab 250 / Paclitaxel 30 / Carboplatin 1 / Radiation, Head and Neck Tumors, Cycle 7-11 (PID1244)Cetuximab 250 / Paclitaxel 40 / Carboplatin 2 / Radiation, Head and Neck Tumors, Cycle 2+ (PID621)Cetuximab 250 / Paclitaxel 80, Head and Neck Tumors, Cycle 2+ (PID708)Cetuximab 250 / Paclitaxel 90 / Carboplatin 2, Head and Neck Tumors, Cycle 2-6 (PID1243)Cetuximab 250 / Radiation, Head and Neck Tumors, Cycle 2+ (PID1195)Cetuximab 250, Head and Neck Tumors, Cycle 2+ (PID1221)Cetuximab 400 / Carboplatin 5 / Fluorouracil 1000, Head and Neck Tumors, C1 (PID623)Cetuximab 400 / Paclitaxel 40 / Carboplatin 2 / Radiation, Head and Neck Tumors, Cycle 1 (PID622)Cetuximab 400 / Paclitaxel 80, Head and Neck Tumors, Cycle 1 (PID707)Cetuximab 400 / Paclitaxel 90 / Carboplatin 2, Head and Neck Tumors, Cycle 1 (PID1242)Cetuximab 400 / Radiation, Head and Neck Tumors, Cycle 1 (PID1194)Cetuximab 400, Head and Neck Tumors, Cycle 1 (PID1220)Cetuximab 500 / Docetaxel 50, Head and Neck Tumors (PID1277)Cetuximab 500, Head and Neck Tumors (PID1241)Cisplatin 100 / Radiation, Head and Neck Tumors (PID1334)Cisplatin 100 / Radiation, Head and Neck Tumors (PID1640)Cisplatin 100 / Radiation, Head and Neck Tumors, adjuvant (PID1291)Cisplatin 100, Head and Neck Tumors (PID1245)Cisplatin 12 / Fluorouracil 600 / Radiation, Head and Neck Tumors, cycle 1-2 (PID2059)Cisplatin 16 / fluorouracil 600, Head and Neck Tumors, cycle 3 (PID2060)Cisplatin 20 / Fluorouracil 600, Head and Neck Tumors, cycle 4 (PID2062)Cisplatin 20 / Fluorouracil 800 / Radiation, Head and Neck Tumors (PID2066)Cisplatin 30 / Radiation, Head and Neck Tumors, adjuvant (PID1240)Cisplatin 40 / Radiation, Head and Neck Tumors (PID1637)Docetaxel 15 / Radiatio, Head and Neck Tumors (PID2259)Docetaxel 65 / Carboplatin 6, Head and Neck Tumors (PID1278)Docetaxel 75 / Cisplatin 75 / Fluorouracil 750, Head and Neck Tumors (PID1102)Fluorouracil 600 / Mitomycin 10 / Radiation, Head and Neck Tumors (PID2058)Methotrexate 40, Head and Neck Tumors (PID1281)Nivolumab 240, Head and Neck Tumors (PID856)Paclitaxel 40 / Carboplatin 1 / Radiation, Head and Neck Tumors (PID2386)Paclitaxel 45 / Carboplatin 1.5 / Radiation, Head and Neck Tumors (PID1295)Paclitaxel 80, Head and Neck Tumors (PID1216)Pembrolizumab 200 / Carboplatin 5 / Fluorouracil 1000, Head and Neck Tumors, first-line (PID1446)Pembrolizumab 200 / Cisplatin 100 / Fluorouracil 1000, Head and Neck Tumors (PID1447)Pembrolizumab 200 / Radiation, Head and Neck Tumors (PID2258)Pembrolizumab 200, Head and Neck Tumors, first-line (PID1445)Pembrolizumab 200, Head and Neck Tumors, Second Line (PID239)Pembrolizumab 400, Head and Neck Tumors (PID1270)